ZAG对结肠腺癌癌症恶病质小鼠脂质代谢的影响

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1624 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the effect of zinc-alpha2-glycoprotein (ZAG) on lipid metabolism of mice with cancer cachexia (CC) using a mouse model of colon adenocarcinoma cachexia. Methods: A mouse model of colon adenocarcinoma cachexia was well established by inoculating mouse colon cancer cell line, colon 26 into BALB/c mice. A total of 18 BALB/c mice were evenly divided into 3 groups randomly: healthy control (HC) group, tumor control (TC) group and cancer cachexia (CC) group (n=6). Adjacent non-tumor tissues and adenocarcinoma of colon (AC) tissues isolated from TC group and CC group were collected to determine ZAG mRNA and protein level. ZAG protein concentration and mRNA level in subcutaneous adipose tissues of each group were determined, while the correlation between ZAG mRNA level and weight loss was confirmed. mRNA expression level of ZAG and adiponectin in serum were measured, and the correlation between them in TC group and CC group was analyzed. Finally, weight was recorded in cancer cachexitic model of mice with colon adenocarcinoma transplantation followed by adenovirus-constructed pcDNA or pcDNA-ZAG injection. Results: ZAG mRNA and protein level of AC tissues and adipose tissues in CC group was significantly higher than those in TC group (P<0.05). ZAG mRNA level was correlated positively with weight loss in adipose tissue. Besides, the serum mRNA levels of ZAG and adiponectin in CC group were significantly higher than those in TC group and were positively correlated. In addition, mice weight was observably reduced after treatment with pcDNA-ZAG (P<0.05). Conclusion: Enhanced ZAG can significantly promote the steatolysis, and affect the weight in colon adenocarcinoma cachexia mice.

Key words： colon adenocarcinoma cancer cachexia zinc-alpha2-glycoprotein adiponectin weight loss mice

Received: 27 May 2017

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Zhang Peichen
	Shi Lingyan
	Zhou Feng
	Wu Wenyi
	Yu Zhen

URL:

https://xb.wmu.edu.cn/EN/ OR https://xb.wmu.edu.cn/EN/Y2018/V48/I2/101

[1] LETILOVIC T, VRHOVAC R. Influence of additional criteria from a definition of cachexia on its prevalence——good or bad thing?[J]. Eur J Clin Nutr, 2013, 67(8): 797-801.
[2] ARGILES J M, BUSQUETS S, STEMMLER B, et al. Cancer cachexia: understanding the molecular basis[J]. Nat Rev Cancer, 2014, 14(11): 754-762.
[3] EBADI M, MAZURAK V C. Potential biomarkers of fat loss as a feature of cancer cachexia[J]. Mediators Inflamm, 2015, 2015: 820934.
[4] WHELAN S A, HE J, LU M, et al. Mass spectrometry (LC-MS/MS) identified proteomic biosignatures of breast cancer in proximal fluid[J]. J Proteome Res,2012, 11(10): 5034-5045.
[5] MRACEK T, DING Q, TZANAVARI T, et al. The adipokine zinc-alpha2-glycoprotein (ZAG) is downregulated with fat mass expansion in obesity[J]. Clin Endocrinol (Oxf), 2010, 72(3): 334-341.
[6] BONETTO A, RUPERT J E, BARRETO R, et al. The colon-26 carcinoma tumor-bearing mouse as a model for the study of cancer cachexia[J]. J Vis Exp, 2016, 30(117): 1-21.
[7] 徐建芳, 周彩存, 张海平, 等. 癌症恶病质与细胞因子的关系及消炎痛干预的实验研究[J]. 中国肺癌杂志, 2004, 7(4): 336-338.
[8] 牛旗, 李同度, 刘爱国, 等. 细胞因子在实验性癌症恶病质中的作用[J]. 中华肿瘤杂志, 2001, 23(5): 382-384.
[9] XIAO X, LI H, QI X, et al. Zinc alpha2 glycoprotein alleviates palmitic acid-induced intracellular lipid accumulation in hepatocytes[J]. Mol Cell Endocrinol, 2017, 439: 155-164.
[10] QU C, ZHOU X, YANG G, et al. The natural logarithm of zinc-alpha2-glycoprotein/HOMA-IR is a better predictor of insulin sensitivity than the product of triglycerides and glucose and the other lipid ratios[J]. Cytokine, 2016, 79: 96-102.
[11] ZHU H J, DING H H, DENG J Y, et al. Inhibition of preadipocyte differentiation and adipogenesis by zinc-alpha2-glycoprotein treatment in 3T3-L1 cells[J]. J Diabetes Investig, 2013, 4(3): 252-260.
[12] FEARON K C, GLASS D J, GUTTRIDGE D C. Cancer cachexia: mediators, signaling, and metabolic pathways[J]. Cell Metab, 2012, 16(2): 153-166.
[13] SHAH N R, BRAVERMAN E R. Measuring adiposity in patients: the utility of body mass index (BMI), percent body fat, and leptin[J]. PloS One, 2012, 7(4): e33308.
[14] WELTERS I D, BING C, DING C, et al. Circulating anti-inflammatory adipokines high molecular weight adiponectin and zinc-alpha2-glycoprotein (ZAG) are inhibited in early sepsis, but increase with clinical recovery: A pilot study[J]. BMC Anesthesiol, 2014, 14: 124.
[15] BING C, BAO Y, JENKINS J, et al. Zinc-alpha2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia[J]. Proc Natl Acad Sci U S A, 2004, 101(8): 2500-2505.
[16] RUSSELL S T, ZIMMERMAN T P, DOMIN B A, et al. Induction of lipolysis in vitro and loss of body fat in vivo by zinc-alpha2-glycoprotein[J]. Biochim Biophys Acta, 2004, 1636(1): 59-68.